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Abstract
Objective: Investigate the clinical management of patients with neo-
plastic wounds by nurses. 
Methods: This is an exploratory study, with qualitative approach, 
conducted in August 2014, with ten clinical nurses of a philanthropic 
hospital that provides care to patients with advanced cancer. Data 
were collected through semi-structured interviews and data analysis 
was performed using the Minayo’s Thematic Analysis Technique, which 
enabled the construction of one category and four subcategories. 
Results: The nurses’ knowledge on the clinical management of 
wounds is weak and has many weaknesses involving patients with 
advanced cancer.
Conclusion: One evidenced the need to invest in continuing educa-
tion and implementation of protocols that support greater autonomy 
of nurses in decision-making, ensuring legal support to these profes-
sionals to improve care for people with neoplastic wounds.
Malignant Neoplastic Wounds: 
Clinical Management Performed by Nurses 
 ORIGINAL 
1  Nurse. PhD Student at the Postgraduate 
Program in Nursing of the Federal 
University of Paraíba. Professor at the 
Graduate Course in Nursing of the 
Federal University of Campina Grande. 
*.
2  Nurse. Federal University of Campina 
Grande. Cuité, Paraíba, Brazil.
3  Nurse. PhD. Professor at the Graduate 
Course in Nursing of the Federal 
University of Campina Grande. Cuité, 
Paraíba, Brazil.
4  Nursing Student. Federal University of 
Campina Grande. Cuité, Paraíba, Brazil.
5  Nurse. Specialist. Professor at the 
Graduate Course in Nursing of the 
Federal University of Campina Grande. 
Cuité, Paraíba, Brazil.
6  Nurse. MSc. Federal University of 
Paraíba. *.
7  Nurse. Federal University of Paraíba. *.
8  Nurse. PhD Student at the Postgraduate 
Program in Nursing of the Federal 
University of Paraíba. *.
9  Nurse. PhD. Professor at the 
Postgraduate Course in Nursing of the 
Federal University of Paraíba. *.
*: João Pessoa, Paraíba, Brazil
Contact information:
Glenda Agra.
Address: Rua Nicola Porto, 251, Manaíra, 
João Pessoa, Paraíba, Brazil. CEP: 58038-
120.
Tel: (55-83-9.9992-2438).
 g.agra@yahoo.com.br
Keywords
Skin Ulcer; Wounds and Injuries; Oncology Nursing; Nursing Care.
Glenda Agra1, Josenilda Pereira dos Santos2, 
Alana Tamar Oliveira de Sousa3, 
Bernadete de Lourdes André Gouveia1, 
Débora Thaíse Freires de Brito4, Elton de Lima Macêdo4, 
Maria Vitória de Souza Medeiros4, Edlene Régis Silva Pimentel5, 
Patrícia Simplício de Oliveira6, Thalys Maynnard Costa Ferreira7, 
Daniele Martins do Nascimento Oliveira8, 
Simone Helena dos Santos Oliveira9, 
Maria Júlia Guimarães Oliveira Soares9, 
Marta Miriam Lopes Costa9
InternatIonal archIves of MedIcIne 
sectIon: oncology
ISSN: 1755-7682
2016
Vol. 9 No. 344
doi: 10.3823/2215
This article is available at: www.intarchmed.com and www.medbrary.com 2
Introduction
The malignant neoplastic wounds are cutaneous 
infiltration of cancerous cells, which generally de-
velop due to the growth of a primary tumor of the 
skin (basal cell carcinoma, squamous, melanoma, 
Kaposi’s sarcoma, cutaneous lymphomas) or any 
malignant tumor metastasis. Other less frequent 
causes are the result of accidental implantation of 
malignant cells in the epithelium in diagnostic pro-
cedures and surgical or chronic wound which, in 
turn, lead to malignancies (Marjolin’s ulcer). [1-3]
The prevalence of those lesions, regardless of 
the anatomic location, is not well documented, 
but there are estimates, from international studies, 
that 5 to 10% of cancer patients develop malig-
nant wounds [2, 3]. Study conducted in Switzer-
land, during six months, found that the prevalence 
of malignant lesions in patients with metastatic 
cancer was 6.6%. [4] 
The skin metastases occur in 0.7 to 10.4% of 
all those patients diagnosed with cancer and 2% 
represent all skin tumors. Metastases may be the 
first clinically silent cancer sign or even an indication 
of tumor recurrence. The appearance of subsequent 
metastasis is variable, but, in general, it occurs du-
ring the first three years after diagnosis. [5-8] Breast, 
lung and gastrointestinal tract cancer and melano-
mas are tumors that have increased susceptibility to 
progress to skin metastases. [9] 
One assumes that skin metastases and malignant 
neoplastic wounds are more common in developing 
countries than developed countries, but the data in 
the literature are too limited to confirm this. One 
postulates that, in the poorest countries, the limita-
tion of education and public awareness along with 
the lack of screening programs are the reasons that 
lead the patient to provide advanced forms of those 
lesions. [10]
However, even with advanced forms of the di-
sease, the survival of patients with malignant neo-
plastic wounds have increased in the last four de-
cades. [11] A retrospective study [12] conducted 
in a palliative care unit with 418 advanced cancer 
patients presenting skin problems (pressure sores, 
malignant neoplastic and others) used multivariate 
analysis and control of co-occurrence of injury, age, 
sex, Charlson’s comorbidity index and Performance 
Scale and revealed the following results: there was 
increased statistically significant risk of death for 
women who had pressure sores; association bet-
ween the presence of several injuries and reduced 
survival; and no association between the presence 
of malignant neoplastic wounds and decreased sur-
vival of patients. Probably, the reduction of survival 
relates to the advancement of the oncological di-
sease and the use of various therapeutic modalities 
for many years.
Malignant neoplastic wounds are a grievance in 
the patient’s life with oncological diseases, because 
they gradually disfigure the body, becoming friable, 
painful, secretive, foul-smelling and often compete 
for mutilations. Those wounds have psychological 
and social effects that can interfere with interper-
sonal relationships, since the patient has feelings 
of rejection, social isolation, anxiety, sadness and 
loneliness. [13-17] 
Malignant neoplastic wounds make the patient 
constantly remind of his/her incurable disease, the 
evil prognosis and, most often, the patient brings 
in his/her speech, during the relational environment 
treatment, the sine qua non condition of death ap-
proaching. Faced with such a situation, the patient 
needs specific care of the injuries. [13-17] 
The treatment of malignant neoplastic wounds 
is a complex issue because it requires evaluation of 
the oncologic etiology, the wound characteristics, 
physical and emotional state of the patient and the 
stage of the wound.
The nurse, as a member of the health team, is 
generally responsible for the care that requires phy-
sical, emotional and social contact. In this condition, 
performing curatives would be part of that care, 
because it is up to him/her to develop skills and 
abilities that enable him/her know and identify in-
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dividual and/or social characteristics of patients with 
malignant wounds, and implement specific actions 
to the identified needs. In this sense, performing 
comfortable and aesthetically acceptable curatives 
for the patient is a challenge for nurses, which 
would contribute both to a more acceptable pre-
sentation of the patient in relation to hit/her social 
image as the satisfaction with him/herself and the 
care received.
Based on this path, the study presents as a gui-
ding question: what is the clinical management per-
formed by nurses towards patients with malignant 
neoplastic wounds? In this perspective, the objective 
of the study was to investigate the clinical manage-
ment of patients with neoplastic injuries by nurses.
This research aims to contribute to the expan-
sion of scientific literature on the theme, as well 
as clarify the professionals on the importance of 
investing in training in oncology nursing, especially 
regarding the care of neoplastic wound, as well as 
sensitizing the hospital care institution to implement 
protocols that support the practice of the nursing 
professional.
Method
This is a qualitative research conducted with nurses, 
developed into a Charitable and Public Hospital in 
the city of Campina Grande/PB, Brazil, which ser-
ves people with oncological diseases, who need to 
perform medical d iagnosis and radiotherapeutic, 
chemotherapeutic, surgical treatment, rehabilitation 
and palliative care.
This is a qualitative research conducted with nur-
ses, developed into a Charitable Hospital in the city 
of Campina Grande/PB, which serves people with 
oncological diseases.
The inclusion criteria to delineate the profile of 
the study participants were nurses who were in la-
bor activity at the time of collection and providing 
care to people diagnosed with cancer presenting 
tumor wounds; the exclusion criteria were nurses 
who were not in labor exercise (such as, vacation, 
maternity leave, sick leave, clearance for teacher tra-
ining). Given that the institution has 21 nurses and 
the research presents qualitative design, the sample 
occurred by saturation, that is, the inclusion of new 
participants ended when the obtained data began 
to repeat, according to the researcher’s evaluation. 
[15]
The inclusion criteria to delineate the profile of 
the study participants were nurses who were in la-
bor activity at the time of collection and providing 
care to people diagnosed with cancer presenting 
tumor wounds. Given that the institution has 21 
nursing assistants and the research presents qualita-
tive design, the sample occurred by saturation, that 
is, the inclusion of new participants ended when 
the obtained data began to repeat, according to 
the researcher’s evaluation. [18] 
The authors constructed the instrument for this 
research, which characterizes by being a script con-
taining questions for a semi-structured interview. 
The script consisted of two parts: the first part 
covered the issues related to socio-demographic, 
academic and professional data of the participating 
nurses (such as age, gender, time of training and 
professional experience) and the second part invol-
ved subjective questions related to knowledge and 
practice of the participating nurses regarding the 
clinical management of neoplastic wounds (such as 
pain, exudate, odor and bleeding management).
When invited to the study, the participants were 
informed about the research objectives. The secre-
cy, anonymity and withdrawal at any time of the 
investigation were secured, prior to presentation 
and signing of the Informed Consent Form (ICF), 
provided at time of interview whose recording has 
been duly authorized, which complied with Resolu-
tion 466/2012 of the National Health Council. The 
study was approved by the Research Ethics Commit-
tee under the CAAE 31103314.9.0000.5182.
The interviews were conducted in private envi-
ronment in August 2014 and lasted about 30 mi-
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nutes. Later, they were transcribed in the form of 
texts and subsequently submitted for validation of 
their statements, prior to completion of the analysis 
of the material. Soon after the successive reading 
of the speeches, one proceeded to the codification 
of the study participants, extracting the speeches 
grouped by similarity, thus being possible to form 
themes. The method used for the analysis was the 
qualitative analysis of Minayo (2010). [18]
In order not to identify the participants, the 
speeches received alphanumeric codes (N1 to N10), 
where “N” stands for “nurse”, plus the interview 
number. Thus, “N1” is the first nurse interviewed.
Results and Discussion
The participants were ten nurses responsible for 
the curative of people with malignant wounds, 
with ages ranging 23-44 years old, training time 
from one to 20 years of service, with experience 
in assisting people with oncological diseases, from 
one to 15 years. When asked about the title, eight 
reported being specialists, one mentioned having 
only graduation and one mentioned having MSc 
degree. Table 1 presents those data:
After collecting data, and from the estimated em-
pirical material, the thematic category Caring for 
malignant neoplastic wounds emerged, which was 
divided into four subcategories: Pain Caring; Taking 
care of exudate and odor; Taking care of bleeding; 
Taking care of necrosis and signs of infection. They 
are presented below: 
Caring for malignant neoplastic wounds
Assistance to people with malignant neoplastic 
wounds presents significant challenges to treatment, 
since, when detected at an advanced stage, they 
have no healing possibilities. Thus, treatment focu-
ses on controlling the symptoms and signs of those 
lesions in order to promote dignity during the dying 
and death process.
Subcategory 1. Pain caring
Patients with malignant neoplastic wounds report 
pain as one of the worst experienced symptoms, 
affecting their quality of life [16]. This type of pain 
associates with neuropathy, that is, pressure and/or 
invasion of the nerve endings and structure resul-
ting from the accelerated growth of the tumor [1], 
injuries cleaning and frequent dressing changes. [19]
Pain management of the participating research 
nurses follow some criteria established by the Mi-
nistry of Health Manual [20], exemplified in the fo-
llowing lines:
In the case of pain, we do analgesia [...] medi-
cation, such as dipyrone and Tramal. There are 
patients we have to administer dolantina.
N1.
Table 1.  Characterization of the research partici-
pants.
N =10
Gender
Female 10
Male -
Age
20 – 30 04
31 - 41 06
Time of academic formation
1 – 5 years 04
6 – 10 years 04
11 – 20 years 02
Time of experience in oncology
Up to 1 year 76.19
2 – 5 years 61.47
6 – 10 years 66.47
11 – 15 years
N =10
Degree
Bachelor 76.19
Specialization 61.47
MSc
Total 10
Source: Research data data, 2014.
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for easing their pain, we change their position 
and position them on the cushion, in order to 
make the patients comfortable. I'm thinking in 
the nursing point of view, without using any me-
dical resource. In the case of severe pain, prescri-
bed medication..
N2.
In pain, we administer the medication, right?.
N3.
One can observe that, through the nurses’ state-
ments, they use non-opioid and opioid analgesics 
for pain relief, as recommended by the Brazilian 
Consensus on Cancer-related Pain Management 
[21]. It is noteworthy that, since 2001, the Ministry 
of Health recommends remedial actions to con-
trol pain, once already advocated since 1986 by 
the World Health Organization, which created the 
Pain Analgesic Ladder, whose purpose is to guide 
the sequential use of drugs, gold standard in the 
treatment of oncological pain [18] and pain ma-
nagement of patients with malignant neoplastic 
wounds. [22-23]
The Pain Analgesic Ladder consists of three steps: 
the first is characterized by mild pain and indica-
tes the use of anti-inflammatory and non-opioid 
analgesics; the second one, by moderate pain, re-
commending weak opioids; the third one, by seve-
re pain, advocating strong opioids. Therefore, it is 
possible to observe that the participants administer 
weak and strong opioids, respectively, for mode-
rate and severe pain, to patients with malignant 
neoplastic wounds [24]. In this context, one infers 
that the service, as well as its nurses, bases their 
interventions on the current scientific literature.
Nevertheless, pain management is complex be-
cause the pain itself (neuropathic) unfolds in anxie-
ty, anguish and apprehension related to the care 
procedures. In this sense, the nurses did not specify 
other actions taken to control pain, such as talking 
with the patients before and during the dressing, 
in order to guide them and distract their attention, 
adjust the time of the curative exchange after the 
patient had already been medicated, irrigate abun-
dantly the primary cover, remove the bandage 
gently and avoid rubbing the wound bed.
The Ministry of Health Manual [20] highlights 
more specific interventions to control pain during 
the course of dressing: using ice on the wound be-
fore and after the procedure, starting the procedu-
re after 30 minutes of oral analgesia, five minutes 
from analgesia subcutaneously or intravenously or 
topically, assessing the need for topical anesthesia 
with 2% lidocaine gel (applied over and around 
the lesion, covering approximately 2 cm of healthy 
tissue).
Besides the application of ice and isolated lido-
caine, there is evidence of therapeutic success to 
control pain using lidocaine and/or morphine asso-
ciated with hydrogel on neoplastic wounds. A stu-
dy carried out with 32 women with invasive ductal 
carcinoma found that the topical use of lidocaine 
2.5%, associated with procaine 2.5% had thera-
peutic success 50% of the sample [24]. The use of 
diamorphine 10mg added to amorphous hydrogel, 
applied directly on the lesion, controlled the pain in 
the first day of the treatment [22, 25]. The topical 
application of morphine sulfate 10 mg/ml in 8 g 
of hydrogel in 16 patients with malignant wound 
revealed that the experimental group had pain re-
lief in comparison with the control group [26]. The 
use of morphine gel with polyhexanide (PHMB) in 
30 patients with painful chronic leg ulcers resul-
ted in pain relief in all patients. In 24 hours after 
the application, the mean pain intensity decreased 
from 7.8 to 4.5. This new development is certainly 
a promising therapeutic alternative for pain control 
in patients with chronic ulcers. [27] 
In order to minimize the trauma induced by fre-
quent dressing removal, it is necessary to invest in 
dressings associated with sealants (zinc oxide), and 
protective barrier creams which are useful in pro-
tecting the surrounding skin [19]. Careful selection 
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of atraumatic and noncompliant covers, such as si-
licone, has been documented to limit skin damage, 
trauma and minimize pain during dressing changes. 
[4]
In addition to the therapeutic modalities mentio-
ned for pain control, it is imperative to emphasize 
that the nurse N2 seeks autonomy of the profession 
when revealing the use of other forms of care that 
do not depend on the medical prescription, such as 
changing positions and using cushions that provide 
pain relief and patient’s comfort.
It is noteworthy that none of the professionals 
inferred about what is behind a neoplastic lesion: 
the patient, with his/her total pain, fears, anxieties 
and afflictions, who feels fragile in body and soul. 
Where is the sensitivity?! One instigates up on a 
care that extends to human dignity, based on a 
dialogical model, in which the being receiving the 
care has voice and can express his/her needs.
Subcategory 2. Taking care of exudate and odor
The exudate in malignant neoplastic wounds relates 
to inflammation, vasodilatation and cell imbalance; 
and when excessive, cause proliferation of anaero-
bic bacteria, which release volatile acids (propionic, 
butyric, valeric, isobutyric, and isovaleric), volatile 
sulfur compounds, putrescine and cadaverine, res-
ponsible for the putrid odor [2, 3]. In this scenario, 
patients with malignant neoplastic wounds consider 
the fetid odor one of the most punishing symptoms, 
due to the disgusting feeling related to it. Moreo-
ver, the unpleasant odor causes vomiting, decreased 
appetite, weight loss and social isolation. [15, 28] 
In this sense, some nurses follow the recommen-
dations proposed by the Ministry of Health [17] and 
some others use contraindicated and even obsolete 
products in the treatment of wounds. 
We clean the exudate. Depending on the amou-
nt, the patient even goes to the operating room 
in order to put a drain.
N1.
exudate is the issue of excessive production, 
right? We evaluate the exudate and the right type 
of dressing for the quantity and odor. Today, for 
the odor, we use calcium alginate, which contains 
silver and activated carbon with silver [...] they are 
the most used.
N2.
for exudate and odor, we use PVPI. Here, we use 
PVPI in almost everything!
N6.
when there are secretion and odor, the doctor 
prescribes furacin and dexamethasone. But, prior 
to them, we wash with chlorhexidine.
N7.
for exudate, we perform the dressing and com-
municate to the doctor, and for the odor, we 
clean with chlorhexidine.
N8.
when there is exudate, we do rigid cleaning three 
times a day, and for the odor, we do the cleaning 
with saline solution or disinfectant or topic PVPI
N9.
The survey participants mentioned that they per-
form the control of exudate and odor in malignant 
neoplastic wounds by cleaning the wound with sa-
line solution and antiseptics, such as chlorhexidine 
and polyvinylpyrrolidone iodine (PVPI) and, subse-
quently, use primary covers, such as calcium algi-
nate with silver and activated carbon with silver. 
Besides those dressings, the participants stressed 
that doctors still prescribe the use of Furacin (Ni-
trofurazone) and dexamethasone to control those 
symptoms.
For lesions cleaning, the saline solution is conside-
red the ideal solution, for its isotonic properties and 
for it does not interfere with the healing process, 
since this solution does not cause tissue damage, 
sensitization or allergy, or alter the normal bacterial 
flora of the skin. [29] 
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Some authors [30] and the National Health Sur-
veillance Agency [31] indicate the use of PVPI only 
for antisepsis of hands and forearms of the surgical 
team and preparation of the skin in during the pre-
operative phase.
Thus, specifically regarding the topical treatment 
of wounds, the indiscriminate use of PVPI by some 
health professionals may likely be associated with 
the lack of knowledge or devaluation of the poten-
tial environmental and toxicological effects direct to 
patients and professional agents. 
Thefore, there is no standard antiseptic to clean 
injuries, resulting in the application of atoxic solu-
tions, such as chlorhexidine, by professionals, and 
toxic, PVPI, by others, on the same lesion. This kind 
of behavior indicates the need for Continuing Edu-
cation in Health, from what nurses know and what 
they have in the locus of work, to awaken the in-
terest of those professionals to provide good qua-
lity care, based on safety and scientific knowledge.
A comparative study verified the microbiostatic 
and microbicide concentration of antiseptics used to 
clean wounds, and the results showed the following 
decreasing effectiveness: polihexanide (PHMB), oc-
tenidine, chlorhexidine, triclosan and PVPI. Regar-
ding the compatibility with the tissue, PHMB and 
octenidine present antiseptic recommendations for 
acute wounds, while, for chronic injuries, chlorhexi-
dine is preferred due to its greater tolerability; and 
PVPI is indicated for skin antisepsis before invasive 
procedures. [32] 
The Ministry of Health Manual [20] recommends, 
for controlling the exudate, absorptive dressings, 
and for odor, in addition to cleaning with saline so-
lution and chlorhexidine, the use of primary covers, 
such as silver sulfadiazine and/or activated charcoal, 
topical metronidazole and aluminum hydroxide. The 
odor in neoplastic wounds is classified into grades I, 
II and III, which require different cares. Thus, from 
the exposed, for controlling the exudate, nurses 
follow partially the recommendations of the afore-
mentioned manual. [20] 
The activated charcoal impregnated with silver 
is suitable for exuding and malodorous wounds, 
because it removes wound exudate by absorption 
and has bactericidal effect, which reduces the odor. 
Calcium alginate, when in contact with exudate or 
blood, forms a fibrous gel, hydrophilic, hemostatic 
and rich in calcium that interacts with the wound 
sodium ions, absorbs the excessive exudate and/or 
blood and maintains the humidity, thus reducing 
the odor. [28] 
In order to control the exudate, studies [3, 15, 28, 
33-35] suggest absorbent non-stick primary covers, 
as alginates or polyurethane foams and hydrofi-
bers. In order to prevent leakage of exudate for the 
clothing, research suggests a secondary coverage, 
such as colostomy bag and geriatric absorbent. [3, 
33, 35] 
With regard to odor, systematic literature review 
[2] found that metronidazole is significantly effective 
in controlling this symptom due to its imidazolic ac-
tion, which acts directly on the DNA of microorga-
nisms, preventing the synthesis of enzymes essential 
for the pathogen to survive. The Ministry of Health 
Manual [20] recommends the use of metronidazole 
topical gel 0.8% in the wound whose odor is grade 
I and/or II; for the grade-III wound, it recommends 
to associate the topical use of metronidazole to the 
systemic one.
Another important care is to inspect the surroun-
ding skin for signs of inflammation, since it becomes 
brittle and with hyperemia, or even macerated due 
to tumor extension, due to radiotherapy and fre-
quent dressing changes. [3, 33, 35] In these cases, 
studies [3, 33, 35] recommend the use of periwound 
protectors such as barrier creams and/or zinc oxide. 
In addition to those precautions, a tubular mesh can 
be used to better secure the secondary cover in an 
extensive wound. [35] 
Studies [24, 36-37] with patients with malignant 
vegetating wounds observed that the use of algi-
nate, hydrofiber, hydrocellular dressings and extra 
absorbent pads controlled the exudate, and the use 
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of activated carbon and metronidazole reduced the 
odor of that kind of wound. 
Subcategory 3. Taking care of bleeding
Bleeding associates with angiogenesis, due to lo-
cal stimulation of the growth factor of the vascu-
lar endothelium. This can occur during dressing or 
spontaneously [38]. Nurses highlighted the bleeding 
control modes for neoplastic wounds: 
for the bleeding, depending on the type of the 
wound, we make a compressive bandage
N1.
when the wound starts bleeding, then you have 
to stop it. I know that there are, in the market, 
some types of dressings that stanch the bleeding 
and stay more days in contact with the wound, 
so that you have adequate time to be able to 
remove it [...] because if you keep removing that 
bandage, you will break it again and the capillary 
bleeding will continue
N2.
in the bleeding, we try to stop it and also admi-
nister the appropriate medication.
N3.
for the bleeding, e use adrenaline in the wound 
or Transamin IV, prescrib  by the doctor. When 
doing the debridement and the wound starts 
bleeding, the doctor tells us to put adrenaline 
on it and it stops bleeding instantly 
N7.
in the case of bleeding, we do tamponade im-
mediately.
N8.
The survey participants mentioned they perform 
pressure dressing as the simplest method to con-
trol bleeding and administer topical adrenaline and 
intravenous tranexamic acid, according to medical 
prescription. It is noteworthy that such behaviors 
are in accordance with the recommendations of the 
Ministry of Health protocol. [20] 
Adrenaline is a vasoconstrictor suitable for skin 
arterioles and capillaries bleeding. However, it 
should be used with caution because it can lead 
to ischemia and necrosis in areas of blood supply 
commitment. The use of fibrinolysis inhibitors, 
such as tranexamic acid and aminocaproic acid, 
is also suitable for controlling the bleeding. [3, 
33, 35, 39] 
One can see that the nurse N2 discloses knowled-
ge of hemostatic covers available in the market that 
remain longer adhered to the wound bed, without 
the need for frequent replacement, thereby minimi-
zing the risk of bleeding. It is noteworthy that the 
institution of the research did not show availability 
of such coverage at the time of data collection. In 
this sense, it is urgent to highlight nursing actions 
that can be performed in order to prevent the po-
tential risk of profuse bleeding, such as irrigating 
the primary cover abundantly and releasing it gently 
from the wound bed.
Besides the direct compression of bleeding ves-
sels (for 10 to 15 minutes), the Ministry of Health 
[20] recommends the direct application of cold sali-
ne solution on the site and/or use of natural hemos-
tatic coverage, such as calcium alginate, with the 
purpose to minimize bleeding. In case those actions 
do not succeed, the nurse should inform the doctor 
so that he/she prescribes vasoconstrictor drugs and/
or antihaemorrhagics.
Recent studies [3, 33, 35, 39] also suggest the use 
of astringents (sucralfate), sclerosing agents (silver 
nitrate) and coagulants (gelatins) to control blee-
dings.
For many patients, the profuse bleeding causes 
anxiety and nervousness, so it is advisable to use 
palliative sedation and dark colors of towels when 
restraining the bleeding vessels, in order to minimi-
ze such psychological and emotional repercussions. 
[20] 
Another aspect worth mentioning is the cons-
tant use of the verb “to tell”, always highlighted in 
the descriptive expression of the nurse N7, especia-
lly when she mentions the treatment for bleeding 
control of neoplastic wound. Verbs are actions of 
the sentences, the words and texts; there is no 
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report regarding the procedure without using the 
verb “to tell”. “To tell” comes from the Latin man-
dare, direct and indirect transitive verb, meaning 
“to require to do”, “order”, “determine”, “have 
the power” or “authority”. Thus, one reflects in 
the following explanatory direction according to 
the participant’s speech: the relationship establis-
hed between health professionals, particularly bet-
ween the doctor and the nurse, is of command 
and not of mutual participation, as expected from 
a multidisciplinary team.
In this sense, one reflects on a possible gap in 
knowledge by the nurse (for example, N7) regar-
ding the care to patients who develop malignant 
neoplastic wounds, which, in turn, interferes with 
the autonomy of the health professional, who is 
also responsible for managing the care.
Subcategory 4. Taking care of necrosis and signs 
of infection
Tumor growth, the decreased local blood supply and 
the loss of tissue viability can lead to necrosis, and, 
consequently, to bacterial colonization, which can 
progress to local and systemic infection [3]. In this 
sense, nurses reveal their actions given such sign.
for necrosis, the hospital does not provide [...] but, 
depending on the patient's condition, sometimes 
they buy those appropriate dressings that help to 
reduce this amount of dead tissue.
N1.
many cases, we have to do debridement. And 
that debridement [...] you do not always get to do 
throughout the wound, right? Some substances 
have a debridement action [...] you put them, and 
that necrosis will be releasing [...]. In some ca-
ses, you may make the mechanical removal with 
tweezers, scissors.
N2.
idepending on the necrosis, we take the patient 
to the operating room for debridement.
N3.
in the necrosis, we use Collagenase.
N5.
One may observe that the nurses know the 
methods for debridement of wounds and the risks 
involved in this procedure, converging with the 
recommendations of the Ministry of Health [20]. 
However, the speech of nurse N1 revealed that 
the research institution does not provide material/
or specific dressings for the management of necro-
sis, leaving the family - only the one with favorable 
and financial conditions - responsible for purchasing 
such products, which would control this symptom, 
one of the most devastating, and originating from 
various complications. Toward this result, one points 
out to a Brazilian health policy frail and psychoso-
cially limited, especially for terminal patients.
Patients with advanced malignancies develop, in 
the last months of life, wounds whose main cha-
racteristic is that they do not heal. For this, the Mi-
nistry of Health [20] publicized a manual with re-
commendations for controlling signs and symptoms 
of those types of injuries, whose main goal is to 
provide relief from suffering, ensure quality of life 
and dignity of the remaining days in the process of 
death and dying. 
In the case of care with necrosis, the best ap-
proach is the autolytic debridement, enzymatic 
[38], but one must evaluate the risks and benefits 
of this procedure given the patient with malignant 
neoplastic wound, since the friability of the lesions 
may cause the potential risk for massive bleeding. 
[38-39]
In this sense, certain factors should be conside-
red before performing the debridement, such as the 
area to be debrided, the presence of local infec-
tions, vascularization and neovascularization of the 
site, the risk of bleeding during or after the proce-
dure, controlling odor resistant to prior therapy and 
general condition of the patient. [39] 
According to the Ministry of Health [20], nurses 
should evaluate the need for debridement conside-
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ring the functional capacity of the patient, as well 
as select the method: autolytic, enzymatic, me-
chanical or surgical. If necessary, authors highlight 
[38-40] that the debridement of malignant neoplas-
tic wounds should be performed in the operating 
room, in view of the need for the use of hemostatic 
devices, such as electrocautery.
In such wounds, removing the debris can be ac-
complished by keeping the site moist, by gently 
cleaning the necrotic areas or using jets of saline 
solution at a pressure of eight to 15 psi (pound 
force per square inch) [40]. When the tumor has 
extensive necrotic tissue, the surgical debridement 
may be indicated to prevent infection, exudate and 
odor control; however, one should consider cases 
when the patient is in palliative care, having in 
mind that this procedure leads to greater physical 
and emotional suffering for him/her and the family.
The survey participants reported using collage-
nase for enzymatic debridement of necrotic areas 
in neoplastic lesions. Collagenase is a proteolytic 
enzyme whose action mechanism is necrolysis, that 
is, native collagen degradation in the wound floor; 
usually recommended for pressure, vasculogenic 
and diabetic ulcers [41]. Regarding malignant neo-
plastic wounds, the Ministry of Health [20] recom-
mends enzymatic debridement; however, it does not 
mention any specific product for this purpose. The 
Ministry of Health [20] points out that collagenase 
is contraindicated in patients with tumor wounds 
at an advanced stage, for it proved ineffective in 
clinical practice of patients in Palliative Care Units. 
The National Health Surveillance Agency [42] warns 
that, if there is no desired effect within 14 days, the 
treatment with collagenase should be discontinued.
Infectious episodes generally relate to a reduc-
tion of the immune response, the proliferation of 
anaerobic microorganisms, and dead tissue on the 
neoplastic wound [2] and those infections can be 
checked by the presence of systemic and local signs, 
that is, fever, increased odor, pain, exudation, color 
change of the wound bed and inflammation [24]. 
In this perspective, the nurses said it is extremely 
important to assess the extent of the infection be-
fore proceeding with the appropriate therapy, as 
highlighted in the statements below.
in the case of infection, we make dressings and 
medication.
N1.
 [...] you have to assess whether it is a local or 
systemic infection. If it is a systemic infection, so 
only the nursing treatment and simple dressing 
do not treat it, right? There has to be a set [...] 
you have to have a bactericidal dressing.
N2.
for infection, we administer antibiotic.
N3.
when the wound is infected, we make the dres-
sing well done so that the infection does not get 
worse, right? 
N6.
when there is infection, we use Furacin and 
Neomycin.
N7.
Nurses reported that the management carried 
out for the control of infection bases on careful 
evaluation and medical and nursing therapy. Nurses 
recognize that the treatment of systemic infections 
covers not only specific nursing care, but also me-
dical treatment and/or more specific dressings. Mo-
reover, it is possible to observe that the nurses are 
concerned to proceed with the dressing effectively, 
in order to improve the condition of the wound and 
prevent future complications. This concern reveals 
the essence of the nursing profession, which sees 
care as an act of zeal for the patient.
Authors [24, 35] recommend some topical pro-
ducts for neoplastic wounds, which act as debriding 
and antimicrobials, being cadexomer iodine and 
PHMB the most emphasized. Cadexomer iodine is 
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a dressing in the form of an ointment containing 
modified starch microspheres, polyethylene glycol 
and 0.9% iodine. The starch cadexomer acts debri-
ding the slough and absorbing the wound exudate; 
it has antimicrobial activity of broad spectrum up 
to 72 hours. 
The PHMB is considered an antimicrobial agent 
which favors the control of microorganisms present 
in infected wounds, since the molecules of this pro-
duct exert their bactericidal effect by aggregation 
mechanisms, mediated by their biguanide cationic 
cores, attracted by the anion to the wall cell of the 
bacteria, which causes its lysis. It also changes the 
permeability of the microbial cell membrane, which 
leads to loss of key components and cell death. [42]
Research [24] obtained therapeutic success using 
PHMB for a period of eight to 12 days on malignant 
wounds at the first signs of local infection, clinica-
lly observed and in cases of suspected biofilm. It 
is noteworthy that the Ministry of Health Manual 
[20] does not specify recommendations for infection 
control. 
Conclusions
The nurses participating in the research follow cer-
tain guidelines proposed by the literature in their 
practices, particularly in the management of pain, 
bleeding, debridement, infection. However, there is 
a lack of suitable materials for this type of wound 
in the research institution; some professionals use 
unsuitable cleaning products and covers, feeling in-
secure when they turn for an assistance guided by 
the biomedical model.
One reflects on an urgent approach of continuing 
healthcare education for those professionals, which 
values their prior knowledge, from what they know, 
offer and may have by raising awareness of mana-
gers for what is appropriate for the patient with 
neoplastic wound.
Thus, this research opens the prospect for new 
proposals that may contribute to the study of the 
subject, especially in health policies that can qualify 
the professional to question as historical subjects 
responsible for authentic care without mutilating 
the facets of an orderly care, associating knowled-
ge, and reflecting the greater good, life, for as long 
as it exists
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